Lanreotide Autogel® for Acromegaly: A New Addition to the Treatment Armamentarium

Treatments in Endocrinology

Volumn 3, Issue 2, 2004, Pages 77-81

  Ciccarelli, Antonio ^a   Daly, Adrian ^a   Beckers, Albert ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AUTOGEL; GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; CYCLOPEPTIDE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ABDOMINAL PAIN; ACROMEGALY; CHOLELITHIASIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE BLOOD LEVEL; HUMAN; INJECTION SITE; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN INDURATION; SLOW DRUG RELEASE; SLOW RELEASE FORMULATION; BLOOD; GEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; GELS; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 1542515274     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403020-00002     Document Type: Review

References (36)

1. Guillemin R, Gerich JE. Somatostatin: physiological and clinical significance. Annu Rev Med 1976; 27: 379-88
2. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991 Nov; 12 (4): 450-82
3. Reichlin S. Somatostatin. N Engl J Med 1983; 309 (24): 1495-501
4. Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 309 (25): 1556-63
5. Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998 Aug; 83 (8): 2646-52
6. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982 Sep 13; 31 (11): 1133-40
7. Raynor K, Murphy WA, Coy DH, et al. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 1993 Jun; 43 (6): 838-44
8. Data on file, Beaufour-Ipsen Laboratories, Slough. 2001
9. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993 Mar; 76 (3): 721-7
10. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994 Sep; 38 (3): 213-9
11. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002 Jan; 87 (1): 99-104
12. Beckers A. Pituitary adenomas [on CD-ROM]. 3rd ed. Liège: Graphmed Ltd, 2003
13. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatoslatin receptor internalization and resistance. Endocr Rev 2003 Feb; 24 (1): 28-47
14. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994 Dec; 135 (6): 2814-7
15. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002 Jul; 87 (7): 3013-8
16. Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997 Oct; 155 Suppl. 1: S3-6
17. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hsstr1-5) in pituitary tumors. Life Sci 1995; 56 (5): 333-42
18. Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30mg). J Clin Endocrinol Metab 2000 Nov; 85 (11):4099-103
19. Colao A, Marzullo P, Ferone D, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999 Jan; 22 (1): 40-7
20. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000 Nov; 53 (5): 577-86
21. Caron P, Morange-Ramos I, Cogne M, et al. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997 Jan; 82 (1): 18-22
22. Sheppard MC. Primary medical therapy for acromegaly. Clin Endocrinol 2003 Apr; 58 (4): 387-99
23. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998 Oct 23; 282 (5389): 737-40
24. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000 Feb; 85 (2): 526-9
25. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994 Jul; 41 (1): 95-102
26. Colao A, Balzano A, Ferone D, et al. Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) 1997 Jul; 47 (1): 23-8
27. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998 Aug; 83 (8): 2730-4
28. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993 May; 86 (5): 293-9
29. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992 Sep; 21 (3): 669-92
30. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996 Aug; 45 (8 Suppl. 1): 72-4
31. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998 Sep; 83 (9):; 3034-40
32. Colar A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly J Clin Endocrinol Metab 2001 Jun; 86 (6): 2779-86
33. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients: a clinical research center study. J Clin Endocrinol Metab 1995 Sep; 80 (9): 2768-75
34. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992 Nov; 117 (9): 711-8
35. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients: Sandostatin LAR Group. Pituitary 1999; 1 (2): 105-14
36. Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998 Mar; 48 (3): 311-6